We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.
- Authors
Krogstad, Paul; Samson, Pearl; Acosta, Edward P; Moye, Jack; Townley, Ellen; Bradford, Sarah; Brown, Emily; Denson, Kayla; Graham, Bobbie; Hovind, Laura; Sise, Thucuma; Teppler, Hedy; Mathiba, Sisinyana Ruth; Fairlie, Lee; Winckler, Jana L; Slade, Gretchen; Meyers, Tammy; Team, International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1101
- Abstract
Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB. Clinical Trials Registration NCT01751568.
- Subjects
DRUG therapy for tuberculosis; RALTEGRAVIR; HIV infections; CLINICAL trials; TREATMENT effectiveness; DOSE-effect relationship in pharmacology; DRUG interactions; RIFAMPIN; GENETIC techniques; DOSAGE forms of drugs; EVALUATION; CHILDREN
- Publication
Journal of the Pediatric Infectious Diseases Society, 2021, Vol 10, Issue 2, p201
- ISSN
2048-7193
- Publication type
Article
- DOI
10.1093/jpids/piaa039